Lee C. Weingart is the Co-Founder and President of Discovery Therapeutics Caribe. With a career spanning over three decades, Mr. Weingart has held various senior and executive roles in regulatory affairs, international trade, and technology. He is also the founder and President of LNE Group, a prominent advocacy and lobbying firm based in Ohio, West Virginia, and Washington DC with a transatlantic reach. Previously, he served as a County Commissioner in Cuyahoga County, Ohio.
Following his term as County Commissioner, Mr. Weingart held high-ranking executive and sales roles in several regional and international technology companies, including Computer Associates International, Inc., and REALOGIC, where he was Chief Administrative Officer, Vice President, and General Counsel.
Driven by a vision to improve healthcare outcomes for millions of Americans with diabetic foot ulcers, Mr. Weingart co-founded DTC in 2020. The company is initially focused on commercializing Heberprot-P® for the United States market, a pioneering treatment with the potential to transform the current treatment paradigm for American patients.
Mr. Weingart received his juris doctor degree, with honors, from The George Washington University National Law Center in 1991. He received his Bachelor of Arts degree, cum laude, in economics and management from DePauw University in 1988.
Jason Smith is the Co-Founder of Discovery Therapeutics Caribe and he serves as the company’s Senior Vice President of Program Management and Business Development.
Mr. Smith has been instrumental in achieving critical business and regulatory milestones for DTC. He leads DTC’s partnership with the Center for Genetic Engineering and Biotechnology (CIGB), overseeing all aspects of strategic planning, program management, regulatory filings, and business development. His efforts have been crucial in driving the success of DTC’s mission by helping to secure funding, overseeing business negotiations, and managing the company’s day-to-day operations.
As SVP, Mr. Smith directs a talented team of scientists, healthcare professionals, clinical and regulatory consultants, and DTC’s collaboration with key opinion leaders (KOLs) in the wound care industry. His leadership was pivotal in the successful submission of DTC’s initial Investigational New Drug (IND) application to conduct a Phase III clinical trial of Heberprot-P® in the United States.
Also serving as Director of LNE Group’s Strategic Advisory practice, Jason brings more than 20 years of experience in managing domestic and international funding pursuits and business consulting engagements that achieve client objectives and deliver bottom line results. Jason helps innovative enterprises to develop technological assets into viable products with large commercial potential. Jason also manages client work to secure government funding in the United States and Europe. Jason and his team have secured hundreds of millions of dollars to support client interests, including technology innovation and expansion projects.
Jason graduated from Ohio University with a B.B.A. in Marketing, Management, and International Business in 2000 and he earned an M.B.A. in 2003.
Dr. Milton Sanchez-Parodi is the Director of Medical Affairs at Discovery Therapeutics Caribe. Board-certified in Family Medicine, Dr. Sanchez-Parodi has dedicated over three decades to clinical practice, alongside 30 years serving as an Emergency Physician.
A Cuban-born U.S. citizen, Dr. Sanchez-Parodi has been actively involved in improving U.S.-Cuba relations since 1985, focusing on medical dialogue and facilitating medical donations to Cuban hospitals. His efforts include organizing delegations to enhance business and medical interactions between the two nations.
With extensive experience in treating patients in hospital settings, clinical practice, and emergency medicine, Dr. Sanchez-Parodi has a profound understanding of diabetic foot ulcers (DFU) across various medical environments. Currently, as a partner and Director of Medical Affairs for DTC, he is pivotal in advancing the introduction of innovative biopharmaceutical treatments in the U.S., particularly in orchestrating clinical trials to address treatment gaps in DFU management.
Dr. Sanchez-Parodi graduated from Universidad de Granada's Facultad de Medicina in Spain and holds a BA in Biology from the University of California, Santa Cruz.
Deirdre Kraimer serves as the Director of Clinical Operations at DTC, where she leads the clinical development of the company's diverse portfolio. Her experience spans a wide range of therapeutic areas, from early-phase trials in rare diseases to complex, medium-sized oncology trials and large, global phase 3 studies in multiple sclerosis and anti-inflammatory indications.
Previously, Deirdre was the Head of Global Clinical Operations at GMP-Orphan SAS in Europe, focusing on rare diseases. She also served as Vice President of Global Clinical Development at Smith and Nephew, specializing in medical devices, and as Global Head of Clinical Study Management at Astellas Pharma.
Deirdre began her career at Pfizer, Inc., where she spent 28 years in various roles of increasing responsibility within Clinical Research and Operations. Her extensive tenure included assignments in both the US and UK, leading teams across the Americas, Europe, Australia, and Asia, which equipped her with a vast range of international clinical and regulatory expertise.
Deirdre holds a Master's degree in Biology from Brown University and a BS in Chemistry from the University of Connecticut.
The Center for Genetic Engineering and Biotechnology (CIGB) is a distinctive Cuban biotechnology company with a mission to research, develop, produce and commercialize novel biotechnological and pharmaceutical products, with a positive impact on human, animal and plant health, and on industrial productions, in harmony with the environment.
Dr. Marta Ayala Ávila, PhD, has been the director of CIGB since January 2021. Bringing over three decades of experience to her role, Dr. Ayala has been a pivotal figure in the field of biotechnology. Her extensive research has focused on the development of innovative technologies using genetic engineering to produce recombinant antibodies, and she has played a significant role in the development of vaccines targeting cancer and macular degeneration.
Copyright © 2024 DISCOVERY THERAPEUTICS CARIBE - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.